title: Monocyte subpopulations and cardiovascular risk in chronic kidney disease.
abstract: Chronic microinflammation and its cellular hallmark, monocyte activation, contribute substantially to the tremendous burden of cardiovascular disease (CVD) in patients with chronic kidney diseases (CKD). Monocyte heterogeneity is widely acknowledged. Cell-surface expression of CD14 and CD16 defines three functionally and phenotypically distinct subsets of monocytes: classical (CD14(++)CD16(-)) monocytes, intermediate (CD14(++)CD16(+)) monocytes, and nonclassical (CD14(+)CD16(++)) monocytes. A growing body of circumstantial evidence suggests that intermediate monocytes, in particular, contribute to the development of atherosclerosis in the general population as well as in patients with CKD. Intermediate monocytes express a unique pattern of chemokine receptors that have been implicated in atherogenesis. Moreover, this subset of monocytes is predisposed to secrete proinflammatory cytokines. Findings from epidemiological studies indicate that numbers of intermediate monocytes increase with worsening renal function, and that high cell counts predict adverse outcomes in patients undergoing dialysis as well as in patients at early stages of CKD. Based on laboratory and clinical data, intermediate monocytes are a promising therapeutic target for CVD in patients with CKD.
authors.affiliation: Saarland University Medical Center, Germany. gunnar.heine@uks.eu
authors.forename: Gunnar H
authors.initials: GH
authors.lastname: Heine
authors.forename: Alberto
authors.initials: A
authors.lastname: Ortiz
authors.forename: Ziad A
authors.initials: ZA
authors.lastname: Massy
authors.forename: Bengt
authors.initials: B
authors.lastname: Lindholm
authors.forename: Andrzej
authors.initials: A
authors.lastname: Wiecek
authors.forename: Alberto
authors.initials: A
authors.lastname: Martínez-Castelao
authors.forename: Adrian
authors.initials: A
authors.lastname: Covic
authors.forename: David
authors.initials: D
authors.lastname: Goldsmith
authors.forename: Gültekin
authors.initials: G
authors.lastname: Süleymanlar
authors.forename: Gérard M
authors.initials: GM
authors.lastname: London
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Parati
authors.forename: Rosa
authors.initials: R
authors.lastname: Sicari
authors.forename: Carmine
authors.initials: C
authors.lastname: Zoccali
authors.forename: Danilo
authors.initials: D
authors.lastname: Fliser
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000276:immunology*; D006801:Humans; D008264:Macrophages / Q000166:cytology / Q000276:immunology; D009000:Monocytes / Q000166:cytology / Q000276:immunology*; D051436:Renal Insufficiency, Chronic / Q000453:epidemiology* / Q000276:immunology*; D012307:Risk Factors